Universal Ibogaine Inc.

Equities

IBO

CA91360F1099

Healthcare Facilities & Services

Market Closed - Toronto S.E. Other stock markets 10:07:00 2024-04-26 am EDT			5-day change	1st Jan Change
0.015 ^CAD	0.00%		0.00%	+200.00%

Apr. 22	Universal Ibogaine Inc. announced that it expects to receive CAD 0.35 million in funding	CI
Apr. 12	Universal Ibogaine Inc. announced that it expects to receive CAD 0.6 million in funding	CI

Universal Ibogaine Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023

February 04, 2024

Universal Ibogaine Inc. reported earnings results for the first quarter ended October 31, 2023. For the first quarter, the company reported sales was CAD 0.646266 million. Net loss was CAD 0.207849 million compared to CAD 0.841961 million a year ago.

Latest news about Universal Ibogaine Inc.

Universal Ibogaine Inc. announced that it expects to receive CAD 0.35 million in funding	Apr. 21	CI
Universal Ibogaine Inc. announced that it expects to receive CAD 0.6 million in funding	Apr. 11	CI
Universal Ibogaine Inc. announced that it has received CAD 0.575576 million in funding	Apr. 09	CI
Ian Rabb No Longer with Universal Ibogaine as Chief Clinics Officer	Apr. 08	CI
Universal Ibogaine Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 29	CI
Universal Ibogaine Inc. announced that it expects to receive CAD 0.8 million in funding	Feb. 21	CI
Universal Ibogaine Inc. announced that it has received CAD 0.417193 million in funding	Feb. 06	CI
Universal Ibogaine Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	Feb. 04	CI
Universal Ibogaine Inc. announced that it expects to receive CAD 1 million in funding	Dec. 19	CI

Chart Universal Ibogaine Inc.

Duration

Period

More charts

Company Profile

Universal Ibogaine Inc. is a Canada-based life sciences company. The Company is focused on developing a network of addiction treatment clinics and undertake a planned clinical trial for research into the use of ibogaine for addiction treatment. Ibogaine is a naturally-occurring molecule derived from the root bark of the iboga tree and other plants. Ibogaine is a neuroactive compound that appears to reset the brains of drug dependent individuals to a pre-addicted state. Ibogaine has demonstrated effectiveness in treating opioid use disorder and it appears to eliminate the painful symptoms of opioid withdrawal and provides a several month window free of drug cravings. Ibogaine targets multiple receptor sites in the brain when it manages dopamine and serotonin circuits and stimulates new brain cell growth.

Sector

Healthcare Facilities & Services

Calendar

2024-06-26 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
UNIVERSAL IBOGAINE INC.	+200.00%	3.19M
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+11.62%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
PURE HEALTH HOLDING	-31.75%	11.77B
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B
DAVITA INC.	+27.44%	11.71B

Other Healthcare Facilities & Services